Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
- PDF / 533,472 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 94 Downloads / 208 Views
NEW THERAPIES FOR CARDIOVASCULAR DISEASE (AA BAVRY, SECTION EDITOR)
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone Juan Simon Rico-Mesa 1 & Averi White 1 & Ashkan Ahmadian-Tehrani 1 & Allen S. Anderson 2
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose of Review We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects. Recent Findings MRAs are well known for their utility in treating heart failure, refractory hypertension, and diverse nephropathies, namely, diabetic nephropathy. As their name denotes, MRAs inhibit the action of aldosterone at the mineralocorticoid receptor, preventing receptor activation. This prevents remodeling, decreases inflammation, and improves proteinuria. There are not significant differences in outcomes between selective and non-selective MRAs. A new selective MRA named finerenone (originally BAY 94-8862) has shown promising results in several trials (ARTS-HF and ARTS-DN) and smaller studies. Finerenone may have a dose-dependent benefit over older MRAs, decreasing rates of albuminuria and levels of BNP and NTProBNP without causing a significant increase in serum potassium levels. This medication is not yet approved as it is still in phase 3 clinical trials (FIGARO-DKD and FIDELIO-DKD trials). Summary MRAs are beneficial in several disease states. Newer medications, such as finerenone, should be considered in patients with heart failure and diabetic nephropathy who may benefit from a reduction in albuminuria and BNP/NT-ProBNP. Data surrounding finerenone are limited to date. However, results from ongoing clinical trials, as well as new trials to evaluate use in other pathologies, could validate the implementation of this medication in daily practice. Keywords Mineralocorticoid receptor antagonists . Finerenone . BAY 94-8862 . Spironolactone . Eplerenone . Aldosterone
Introduction This article is part of the Topical Collection on New Therapies for Cardiovascular Disease * Allen S. Anderson [email protected] Juan Simon Rico-Mesa [email protected] Averi White [email protected] Ashkan Ahmadian-Tehrani [email protected] 1
Department of Medicine, Division of Internal Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA
2
Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX 78229, USA
Diuretics are a cornerstone in the management of hypertension, heart failure, chronic kidney disease (CKD), and numerous hypervolemic disorders. Various classes of diuretics work on different channels along the nephron increasing sodium excretion through urination. The renin–angiotensin–aldosterone system (RAAS) is a neurohormonal homeostasis path
Data Loading...
